0.00Open0.00Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover0.00%IV-31.48%PremiumJan 17, 2025Expiry Date8.38Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.25Leverage Ratio--Theta--Rho--Eff Leverage--Vega
XOMA Corp Stock Discussion
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Thursday, 19th December at 7:30 am
EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock:
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ: XOMAP) shall receive a cash dividend equal to $0.53906 p...
XOMA Royalty Acquires 50% of Twist Bioscience's Royalty, Milestone Economics for $15M
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
$Dyne Therapeutics (DYN.US)$ 4% Closing of public offering
$Geron (GERN.US)$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (ZEAL.US)$ 2% Capital increase
$XOMA Corp (XOMA.US)$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences (CLRB.US)$ 1% Topline results @ conf. call
$CytomX (CTMX.US)$ 0% Present @ B. Riley Sec. Conf. '24
No comment yet